Postes actifs de Sander van Berkel
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
SynAffix BV
 SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Directeur Technique/Scientifique/R&D | 01/01/2010 | - |
| Fondateur | 01/01/2010 | - |
Historique de carrière de Sander van Berkel
Formation de Sander van Berkel
| Radboud University Nijmegen | Graduate Degree |
Statistiques
Internationale
| Pays-Bas | 3 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Graduate Degree | 1 |
Sectorielle
| Health Technology | 2 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
SynAffix BV
SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Health Technology |
- Bourse
- Insiders
- Sander van Berkel
- Expérience
